by Kim O’Connell, Suzy Madar and James Ellsmore
In a widely anticipated decision, the High Court has upheld a decision of the Full Federal Court that AstraZeneca’s patent relating to low dosages of rosuvastatin is invalid for want of inventive step.
Rosuvastatin is used in the treatment of high cholesterol and is marketed by AstraZeneca as Crestor. The decision will be a relief for companies that have already launched generic versions of rosuvastatin.
For more analysis on the decision, click here.